Association of IL-22 and IL-22RA1 gene variants in Iranian patients with colorectal cancer IL-22 and IL-22RA1 genes SNPs and CRC
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. Supplement 1 (2021),
30 December 2021
https://doi.org/10.22037/ghfbb.vi.2423
Abstract
Aim: In the current study, it was hypothesized that single nucleotide polymorphisms (SNPs) in the regulatory region of the IL-22 signaling pathway genes, including IL-22 and IL-22RA1 variants, may be associated with CRC susceptibility.
Background: The important role of pro-inflammatory cytokines during tumorigenesis is well-established. In recent years, IL-22 has been linked with colorectal cancer (CRC) through a number of mechanistic and observational studies
Methods: The association of four polymorphisms in the IL-22 (rs1179251 and rs1179246) and IL-22RA1 (rs4648936 and rs10794665) genes with CRC risk were studied using a case-control design with 304 cases and 345 controls from the Iranian population. All 649 subjects were evaluated by PCR–RFLP method.
Results: No significant difference was found in genotype and allele frequencies between the cases and controls for either IL-22 and IL-22RA1 gene variants or CRC risk before or after adjusting for confounders.
Conclusion: The current findings do not present any significant evidence for associations between variants in IL-22 signaling pathway genes and CRC. Complementary studies with greater sample sizes may be necessary to fully elucidate the nature of these associations.
Keywords:
- Colorectal cancer
- Interleukin-22 gene
- Interleukin-22 receptor A1 gene
- single nucleotide polymorphism
- PCR-RFLP
How to Cite
Mohebbi, S. R., Karimi, K. ., Rostami, F. ., Kazemian, S. ., Azimzadeh, P. ., Mirtalebi, H. ., Nazemalhosseini-Mojarad, E. ., Asadzadeh Aghdaei, H. ., Vafaee, R. ., & Heydari, M. H. . (2021). Association of IL-22 and IL-22RA1 gene variants in Iranian patients with colorectal cancer: IL-22 and IL-22RA1 genes SNPs and CRC. Gastroenterology and Hepatology from Bed to Bench, 14(Supplement 1). https://doi.org/10.22037/ghfbb.vi.2423
References
1. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nature reviews Genetics. 2009;10(6):353-8.
2. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods in molecular biology (Clifton, NJ). 2009;471:3-29.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;58(2):71-96.
4. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719):1030-47.
5. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Seminars in cancer biology. 2004;14(6):433-9.
6. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? Journal of immunology (Baltimore, Md : 1950). 2002;168(11):5397-402.
7. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. The Journal of biological chemistry. 2000;275(40):31335-9.
8. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. The Journal of biological chemistry. 2001;276(4):2725-32.
9. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology (Baltimore, Md). 2004;39(5):1332-42.
10. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Advances in immunology. 2010;107:1-29.
11. Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. American journal of respiratory cell and molecular biology. 2011;44(3):369-76.
12. Shioya M, Andoh A, Kakinoki S, Nishida A, Fujiyama Y. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas. 2008;36(2):197-9.
13. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas are a target of interleukin-22. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2001;21(12):1047-53.
14. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC cancer. 2013;13:59.
15. Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer causes & control : CCC. 2010;21(8):1165-70.
16. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC cancer. 2013;13(1):59.
17. Nagakawa H, Shimozato O, Yu L, Takiguchi Y, Tatsumi K, Kuriyama T, et al. Expression of Interleukin‐22 in Murine Carcinoma Cells did not Influence Tumour Growth In Vivo but did Improve Survival of the Inoculated Hosts. Scandinavian journal of immunology. 2004;60(5):449-54.
18. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. International immunopharmacology. 2004;4(5):679-91.
19. Ziesché E, Bachmann M, Kleinert H, Pfeilschifter J, Mühl H. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. Journal of Biological Chemistry. 2007;282(22):16006-15.
20. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006;290(4):G827-G38.
21. Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. The Journal of Immunology. 2005;174(6):3695-702.
22. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. The Journal of clinical investigation. 2008;118(2):534.
23. Sekikawa A, Fukui H, Suzuki K, Karibe T, Fujii S, Ichikawa K, et al. Involvement of the IL-22/REG Iα axis in ulcerative colitis. Laboratory Investigation. 2010;90(3):496-505.
24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual review of immunology. 2001;19(1):683-765.
25. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. European journal of cancer. 2005;41(16):2502-12.
26. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nature Clinical Practice Oncology. 2005;2(6):315-24.
27. Bromberg J. Stat proteins and oncogenesis. Journal of Clinical Investigation. 2002;109(9):1139-42.
28. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin‐22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis & Rheumatism. 2005;52(4):1037-46.
29. Whittington HA, Armstrong L, Uppington KM, Millar AB. Interleukin-22: a potential immunomodulatory molecule in the lung. American journal of respiratory cell and molecular biology. 2004;31(2):220-6.
30. Wolk K, Witte E, Hoffmann U, Doecke W-D, Endesfelder S, Asadullah K, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. The Journal of Immunology. 2007;178(9):5973-81.
31. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005;2(2):92-100.
32. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129(3):969-84.
33. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. The Journal of experimental medicine. 2009;206(7):1465-72.
34. Akbari Z, Safari-Alighiarloo N, Taleghani MY, Mirfakhar FS, Asadzadeh Aghdaei H, Vahedi M, et al. Polymorphism of SMAD7 gene (rs2337104) and risk of colorectal cancer in an Iranian population: a case-control study. Gastroenterology and hepatology from bed to bench. 2014;7(4):198-205.
35. Mahmoudi T, Arkani M, Karimi K, Safaei A, Rostami F, Arbabi E, et al. The -4817 G>A (rs2238136) variant of the vitamin D receptor gene: a probable risk factor for colorectal cancer. Molecular biology reports. 2012;39(5):5277-82.
36. Azimzadeh P, Romani S, Mohebbi SR, Mahmoudi T, Vahedi M, Fatemi SR, et al. Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. Cancer genetics. 2012;205(10):501-7.
37. Azimzadeh P, Romani S, Mirtalebi H, Fatemi SR, Kazemian S, Khanyaghma M, et al. Association of co-stimulatory human B-lymphocyte antigen B7-2 (CD86) gene polymorphism with colorectal cancer risk. Gastroenterology and hepatology from bed to bench. 2013;6(2):86-91.
38. Kashfi SM, Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Mashayekhi K, Azimzadeh P, Romani S, et al. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(2):2119-26.
39. Ma G, Liu H, Du M, Zhang G, Lin Y, Ge Y, et al. A genetic variation in the CpG island of pseudogene GBAP1 promoter is associated with gastric cancer susceptibility. Cancer. 2019;125(14):2465-73.
40. Liu W, Xiao H, Wu S, Liu H, Luo B. MAP9 single nucleotide polymorphism rs1058992 is a risk of EBV-associated gastric carcinoma in Chinese population. Acta virologica. 2018;62(4):435-40.
41. Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Azimzadeh P, Goudarzi F, Mohammad Alizadeh AH, Haghazali M, et al. TGF-beta1 polymorphisms -509 C>T and +915 G>C and risk of pancreatic cancer. Gastroenterology and hepatology from bed to bench. 2017;10(1):14-20.
42. Jiang D, Xu L, Ni J, Zhang J, Cai M, Shen L. Functional polymorphisms in LncRNA HOTAIR contribute to susceptibility of pancreatic cancer. Cancer cell international. 2019;19:47.
43. Xu X, Qian D, Liu H, Cruz D, Luo S, Walsh KM, et al. Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. Molecular carcinogenesis. 2019;58(8):1338-48.
44. Shoraka S, Mohebbi SR, Hosseini SM, Hosseini Razavi A, Hatami Y, Sharifian A, et al. Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population. Microbial pathogenesis. 2019;128:263-7.
45. Khanizadeh S, Ravanshad M, Mohebbi SR, Naghoosi H, Abrahim Tahaei M, Mousavi Nasab SD, et al. Polymorphisms within the Promoter Region of the Gamma Interferon (IFN-gamma) Receptor1 Gene are Associated with the Susceptibility to Chronic HBV Infection in an Iranian Population. Hepatitis monthly. 2012;12(11):e7283.
46. Khanizadeh S, Hasanvand B, Nikoo HR, Anbari K, Adhikary H, Shirkhani S, et al. Association between miRNA-146a rs2910164 (G/C) polymorphism with the susceptibility to chronic HBV infection and spontaneous viral clearance in an Iranian population. Journal of medical virology. 2019;91(6):1063-8.
47. Karkhane M, Mohebbi SR, Sharifian A, Ghaemi A, Asadzadeh Aghdaei H, Zali MR. A gene variation of Interferon Gamma Receptor-I promoter (rs1327474A>G) and chronic hepatitis C virus infection. Gastroenterology and hepatology from bed to bench. 2019;12(1):46-51.
48. Karkhane M, Mohebbi SR, Azimzadeh P, Avarandeh H, Kazemian S, Sharifian A, et al. Genetic association between a single nucleotide polymorphism in Interleukin-16 (rs4072111) and susceptibility to chronic HCV infection in an Iranian population. Gastroenterology and hepatology from bed to bench. 2018;11(1):42-7.
49. Real LM, Fernandez-Fuertes M, Saez ME, Rivero-Juarez A, Frias M, Tellez F, et al. A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). Liver international : official journal of the International Association for the Study of the Liver. 2019.
50. Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-alpha mRNA expression level and the rs1799964 polymorphism of the TNF-alpha gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomedical reports. 2017;6(6):698-702.
51. Karimkhani S, Chaleshi V, Balaii H, Tarban P, Nourian M, Irani S, et al. Lack of Association between Interleukin 23R (IL-23R) rs10889677 Polymorphism and Inflammatory Bowel Disease Susceptibility In an Iranian Population. Reports of biochemistry & molecular biology. 2018;7(1):16-22.
52. Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, et al. Influence of IL‐10RA and IL‐22 polymorphisms on outcome of hepatitis C virus infection. Liver International. 2007;27(8):1134-43.
53. Endam LM, Bossé Y, Filali-Mouhim A, Cormier C, Boisvert P, Boulet L-P, et al. Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngology-Head and Neck Surgery. 2009;140(5):741-7.
2. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods in molecular biology (Clifton, NJ). 2009;471:3-29.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;58(2):71-96.
4. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719):1030-47.
5. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Seminars in cancer biology. 2004;14(6):433-9.
6. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? Journal of immunology (Baltimore, Md : 1950). 2002;168(11):5397-402.
7. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. The Journal of biological chemistry. 2000;275(40):31335-9.
8. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. The Journal of biological chemistry. 2001;276(4):2725-32.
9. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology (Baltimore, Md). 2004;39(5):1332-42.
10. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Advances in immunology. 2010;107:1-29.
11. Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. American journal of respiratory cell and molecular biology. 2011;44(3):369-76.
12. Shioya M, Andoh A, Kakinoki S, Nishida A, Fujiyama Y. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas. 2008;36(2):197-9.
13. Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. Acinar cells of the pancreas are a target of interleukin-22. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2001;21(12):1047-53.
14. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC cancer. 2013;13:59.
15. Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer causes & control : CCC. 2010;21(8):1165-70.
16. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC cancer. 2013;13(1):59.
17. Nagakawa H, Shimozato O, Yu L, Takiguchi Y, Tatsumi K, Kuriyama T, et al. Expression of Interleukin‐22 in Murine Carcinoma Cells did not Influence Tumour Growth In Vivo but did Improve Survival of the Inoculated Hosts. Scandinavian journal of immunology. 2004;60(5):449-54.
18. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. International immunopharmacology. 2004;4(5):679-91.
19. Ziesché E, Bachmann M, Kleinert H, Pfeilschifter J, Mühl H. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. Journal of Biological Chemistry. 2007;282(22):16006-15.
20. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006;290(4):G827-G38.
21. Boniface K, Bernard F-X, Garcia M, Gurney AL, Lecron J-C, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. The Journal of Immunology. 2005;174(6):3695-702.
22. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. The Journal of clinical investigation. 2008;118(2):534.
23. Sekikawa A, Fukui H, Suzuki K, Karibe T, Fujii S, Ichikawa K, et al. Involvement of the IL-22/REG Iα axis in ulcerative colitis. Laboratory Investigation. 2010;90(3):496-505.
24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual review of immunology. 2001;19(1):683-765.
25. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. European journal of cancer. 2005;41(16):2502-12.
26. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nature Clinical Practice Oncology. 2005;2(6):315-24.
27. Bromberg J. Stat proteins and oncogenesis. Journal of Clinical Investigation. 2002;109(9):1139-42.
28. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin‐22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis & Rheumatism. 2005;52(4):1037-46.
29. Whittington HA, Armstrong L, Uppington KM, Millar AB. Interleukin-22: a potential immunomodulatory molecule in the lung. American journal of respiratory cell and molecular biology. 2004;31(2):220-6.
30. Wolk K, Witte E, Hoffmann U, Doecke W-D, Endesfelder S, Asadullah K, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. The Journal of Immunology. 2007;178(9):5973-81.
31. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005;2(2):92-100.
32. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129(3):969-84.
33. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. The Journal of experimental medicine. 2009;206(7):1465-72.
34. Akbari Z, Safari-Alighiarloo N, Taleghani MY, Mirfakhar FS, Asadzadeh Aghdaei H, Vahedi M, et al. Polymorphism of SMAD7 gene (rs2337104) and risk of colorectal cancer in an Iranian population: a case-control study. Gastroenterology and hepatology from bed to bench. 2014;7(4):198-205.
35. Mahmoudi T, Arkani M, Karimi K, Safaei A, Rostami F, Arbabi E, et al. The -4817 G>A (rs2238136) variant of the vitamin D receptor gene: a probable risk factor for colorectal cancer. Molecular biology reports. 2012;39(5):5277-82.
36. Azimzadeh P, Romani S, Mohebbi SR, Mahmoudi T, Vahedi M, Fatemi SR, et al. Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. Cancer genetics. 2012;205(10):501-7.
37. Azimzadeh P, Romani S, Mirtalebi H, Fatemi SR, Kazemian S, Khanyaghma M, et al. Association of co-stimulatory human B-lymphocyte antigen B7-2 (CD86) gene polymorphism with colorectal cancer risk. Gastroenterology and hepatology from bed to bench. 2013;6(2):86-91.
38. Kashfi SM, Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Mashayekhi K, Azimzadeh P, Romani S, et al. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(2):2119-26.
39. Ma G, Liu H, Du M, Zhang G, Lin Y, Ge Y, et al. A genetic variation in the CpG island of pseudogene GBAP1 promoter is associated with gastric cancer susceptibility. Cancer. 2019;125(14):2465-73.
40. Liu W, Xiao H, Wu S, Liu H, Luo B. MAP9 single nucleotide polymorphism rs1058992 is a risk of EBV-associated gastric carcinoma in Chinese population. Acta virologica. 2018;62(4):435-40.
41. Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Azimzadeh P, Goudarzi F, Mohammad Alizadeh AH, Haghazali M, et al. TGF-beta1 polymorphisms -509 C>T and +915 G>C and risk of pancreatic cancer. Gastroenterology and hepatology from bed to bench. 2017;10(1):14-20.
42. Jiang D, Xu L, Ni J, Zhang J, Cai M, Shen L. Functional polymorphisms in LncRNA HOTAIR contribute to susceptibility of pancreatic cancer. Cancer cell international. 2019;19:47.
43. Xu X, Qian D, Liu H, Cruz D, Luo S, Walsh KM, et al. Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. Molecular carcinogenesis. 2019;58(8):1338-48.
44. Shoraka S, Mohebbi SR, Hosseini SM, Hosseini Razavi A, Hatami Y, Sharifian A, et al. Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population. Microbial pathogenesis. 2019;128:263-7.
45. Khanizadeh S, Ravanshad M, Mohebbi SR, Naghoosi H, Abrahim Tahaei M, Mousavi Nasab SD, et al. Polymorphisms within the Promoter Region of the Gamma Interferon (IFN-gamma) Receptor1 Gene are Associated with the Susceptibility to Chronic HBV Infection in an Iranian Population. Hepatitis monthly. 2012;12(11):e7283.
46. Khanizadeh S, Hasanvand B, Nikoo HR, Anbari K, Adhikary H, Shirkhani S, et al. Association between miRNA-146a rs2910164 (G/C) polymorphism with the susceptibility to chronic HBV infection and spontaneous viral clearance in an Iranian population. Journal of medical virology. 2019;91(6):1063-8.
47. Karkhane M, Mohebbi SR, Sharifian A, Ghaemi A, Asadzadeh Aghdaei H, Zali MR. A gene variation of Interferon Gamma Receptor-I promoter (rs1327474A>G) and chronic hepatitis C virus infection. Gastroenterology and hepatology from bed to bench. 2019;12(1):46-51.
48. Karkhane M, Mohebbi SR, Azimzadeh P, Avarandeh H, Kazemian S, Sharifian A, et al. Genetic association between a single nucleotide polymorphism in Interleukin-16 (rs4072111) and susceptibility to chronic HCV infection in an Iranian population. Gastroenterology and hepatology from bed to bench. 2018;11(1):42-7.
49. Real LM, Fernandez-Fuertes M, Saez ME, Rivero-Juarez A, Frias M, Tellez F, et al. A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). Liver international : official journal of the International Association for the Study of the Liver. 2019.
50. Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-alpha mRNA expression level and the rs1799964 polymorphism of the TNF-alpha gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomedical reports. 2017;6(6):698-702.
51. Karimkhani S, Chaleshi V, Balaii H, Tarban P, Nourian M, Irani S, et al. Lack of Association between Interleukin 23R (IL-23R) rs10889677 Polymorphism and Inflammatory Bowel Disease Susceptibility In an Iranian Population. Reports of biochemistry & molecular biology. 2018;7(1):16-22.
52. Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, et al. Influence of IL‐10RA and IL‐22 polymorphisms on outcome of hepatitis C virus infection. Liver International. 2007;27(8):1134-43.
53. Endam LM, Bossé Y, Filali-Mouhim A, Cormier C, Boisvert P, Boulet L-P, et al. Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngology-Head and Neck Surgery. 2009;140(5):741-7.
- Abstract Viewed: 86 times
- pdf Downloaded: 44 times